Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 26 Jul 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atorvastatin (Primary) ; CAT 2054 (Primary)
Indications Hypercholesterolaemia
Focus Proof of concept; Therapeutic Use
Sponsors Astria Therapeutics; Catabasis Pharmaceuticals

Most Recent Events

15 Jul 2016 Status changed from active, no longer recruiting to completed.
07 Jun 2016 Results published in a Catabasis Pharmaceuticals media release.
07 Jun 2016 Primary endpoint (Percent change in LDL-C from baseline in patients with hypercholesterolemia.) has not been met, according to a Catabasis Pharmaceuticals media release.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com